162 related articles for article (PubMed ID: 2130925)
41. Fibrinogen Matsumoto I: a gamma 364 Asp-->His (GAT-->CAT) substitution associated with defective fibrin polymerization.
Okumura N; Furihata K; Terasawa F; Nakagoshi R; Ueno I; Katsuyama T
Thromb Haemost; 1996 Jun; 75(6):887-91. PubMed ID: 8822581
[TBL] [Abstract][Full Text] [Related]
42. Fibrinogen Seattle II: congenital dysfibrinogenemia with an Arg (A alpha 16)----his substitution.
Ebert RF; Schreiler WE; Bell WR
Thromb Res; 1986 Jul; 43(1):7-13. PubMed ID: 3726812
[TBL] [Abstract][Full Text] [Related]
43. Fibrinogen Mitaka II: a hereditary dysfibrinogen with defective thrombin binding caused by an A alpha Glu-11 to Gly substitution.
Niwa K; Yaginuma A; Nakanishi M; Wada Y; Sugo T; Asakura S; Watanabe N; Matsuda M
Blood; 1993 Dec; 82(12):3658-63. PubMed ID: 7903170
[TBL] [Abstract][Full Text] [Related]
44. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization.
Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL
Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436
[TBL] [Abstract][Full Text] [Related]
45. Quantifying thrombin-catalyzed release of fibrinopeptides from fibrinogen using high-performance liquid chromatography.
Ng AS; Lewis SD; Shafer JA
Methods Enzymol; 1993; 222():341-58. PubMed ID: 8412803
[No Abstract] [Full Text] [Related]
46. Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aalpha Arg-16----His substitution.
Southan C; Lane DA; Bode W; Henschen A
Eur J Biochem; 1985 Mar; 147(3):593-600. PubMed ID: 3979390
[TBL] [Abstract][Full Text] [Related]
47. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (A alpha 16 Arg----His) containing heterodimeric molecules.
Siebenlist KR; Prchal JT; Mosesson MW
Blood; 1988 Mar; 71(3):613-8. PubMed ID: 3345340
[TBL] [Abstract][Full Text] [Related]
48. Fibrinogen Saint-Germain I: a case of the heterozygous Aalpha GLY 12 --> VAL fibrinogen variant.
Mathonnet F; Peltier JY; Detruit H; de Raucourt E; Alvarez JC; Mazmanian GM; de Mazancourt P
Blood Coagul Fibrinolysis; 2002 Mar; 13(2):149-53. PubMed ID: 11914657
[TBL] [Abstract][Full Text] [Related]
49. Fibrinogen Oviedo I. A new Spanish dysfibrinogenaemia.
Fernández FJ; Rodríguez Pinto C; Páramo J; Cuesta B; Collado M; Rocha E
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):571-5. PubMed ID: 2133236
[TBL] [Abstract][Full Text] [Related]
50. Fibrinogen Longmont. A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization.
Lounes KC; Lefkowitz JB; Coates AI; Hantgan RR; Henschen-Edman A; Lord ST
Ann N Y Acad Sci; 2001; 936():129-32. PubMed ID: 11460470
[TBL] [Abstract][Full Text] [Related]
51. A new genetic fibrinogen variant (fibrinogen Erfurt I). Structurally characterized by an abnormal B beta-chain and present both in plasma and platelets.
Meyer M; Schellenberg I; Vogel G; Bischoff I
Thromb Haemost; 1988 Apr; 59(2):138-42. PubMed ID: 3388290
[TBL] [Abstract][Full Text] [Related]
52. Fibrinogen Magdeburg I: a novel variant of human fibrinogen with an amino acid exchange in the fibrinopeptide A (Aalpha 9, Leu-->Pro).
Meyer M; Kutscher G; Stürzebecher J; Riesener G; Lutze G
Thromb Res; 2003 Jan; 109(2-3):145-51. PubMed ID: 12706644
[TBL] [Abstract][Full Text] [Related]
53. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.
Galanakis DK; Neerman-Arbez M; Scheiner T; Henschen A; Hubbs D; Nagaswami C; Weisel JW
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):731-7. PubMed ID: 17982313
[TBL] [Abstract][Full Text] [Related]
54. A kinetic method for characterization of heterogenous fibrinogen and its application to fibrinogen Grand Rapids, a congenital dysfibrinogenemia.
Higgins DL; Lewis SD; Penner JA; Shafer JA
Thromb Haemost; 1982 Oct; 48(2):182-6. PubMed ID: 6217579
[TBL] [Abstract][Full Text] [Related]
55. Fibrinogens Kosai and Ogasa: Bbeta15Gly-->Cys (GGT-->TGT) substitution associated with impairment of fibrinopeptide B release and lateral aggregation.
Hirota-Kawadobora M; Terasawa F; Yonekawa O; Sahara N; Shimizu E; Okumura N; Katsuyama T; Shigematsu H
J Thromb Haemost; 2003 Feb; 1(2):275-83. PubMed ID: 12871501
[TBL] [Abstract][Full Text] [Related]
56. Fibrinogen Stony Brook II: partial characterization of a heterozygously transmitted peptide A anomaly.
Galanakis DK; Hultin M
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):567-70. PubMed ID: 2133235
[TBL] [Abstract][Full Text] [Related]
57. Fibrinogen Matsumoto III: a variant with gamma275 Arg-->Cys (CGC-->TGC)--comparison of fibrin polymerization properties with those of Matsumoto I (gamma364 Asp-->His) and Matsumoto II (gamma308 Asn-->Lys).
Terasawa F; Okumura N; Higuchi Y; Ishikawa S; Tozuka M; Ishida F; Kitano K; Katsuyama T
Thromb Haemost; 1999 May; 81(5):763-6. PubMed ID: 10365751
[TBL] [Abstract][Full Text] [Related]
58. Hereditary dysfibrinogenaemia: structural and functional studies on three fibrinogen variants.
Meyer M; Vogel G; Gromnica-Ihle E; Schellenberg I; Ostermann G
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):499-502. PubMed ID: 2465961
[TBL] [Abstract][Full Text] [Related]
59. Strategy for recombinant multichain protein synthesis: fibrinogen B beta-chain variants as thrombin substrates.
Lord ST; Strickland E; Jayjock E
Biochemistry; 1996 Feb; 35(7):2342-8. PubMed ID: 8652575
[TBL] [Abstract][Full Text] [Related]
60. The fibrinogenopathies.
Morse EE
Ann Clin Lab Sci; 1978; 8(3):234-8. PubMed ID: 350125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
